MADRIGAL PHARMACEUTICALS, INC. 8-K

What Happened
Madrigal Pharmaceuticals, Inc. (MDGL) announced its financial results for the quarter ended March 31, 2026 in a press release dated May 6, 2026. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8-K filed the same day. The filing states the exhibit is furnished (not “filed”) for purposes of Section 18 of the Exchange Act.

Key Details

• Filing date: May 6, 2026; reporting period: quarter ended March 31, 2026.
• The press release reporting the quarterly results is included as Exhibit 99.1 to the Form 8-K.
• The Form 8-K cites Item 2.02 (Results of Operations and Financial Condition) and includes standard disclosure that the press release is furnished, not filed, and therefore not subject to Section 18 liabilities.
• Report signed by Mardi Dier, Executive Vice President and Chief Financial Officer, on May 6, 2026.

Why It Matters
This 8-K signals Madrigal has released its latest quarterly results (earnings, revenue and other financial metrics) to the market; investors should review the Exhibit 99.1 press release for the specific numbers and management commentary. The “furnished, not filed” designation is standard and limits certain legal liabilities but does not change the substance of the reported results. If you follow MDGL, check the press release and the company’s investor relations page for the detailed financials and any accompanying call or presentation.